Business
Total Voting Rights
Total Voting Rights.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9237K Sareum Holdings PLC 30 June 2014 \n\n\n\n\n(AIM : SAR)\n\n\n30 June 2014\n\n\n\n \nSareum Holdings plc\n \n(\"Sareum\" or \"the Company\")\n \nTotal Voting Rights\n \nThe Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:\n \n\n\n\n\n\n\nTotal number of shares in issue\n\n\nTotal number of voting rights\n\n\n\n\nOrdinary Shares of 0.025 pence each\n\n\n1,910,038,273\n\n\n1,910,038,273\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nThe above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.\n \n\n\n\nFor further information:\n\n\n\n\n\n\n\n \nSareum Holdings plc \nTim Mitchell\n\n\n \n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nSanlam Securities UK Limited (Nomad) \nSimon Clements / James Thomas\n\n\n \n020 7628 2200\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker) \nClaire Noyce / William Lynne\n\n\n \n0203 713 4581/ 4582\n\n\n\n\n\n\n\n\n\n\n\n\nThe Communications Portfolio Limited (Media enquiries)\nAriane Comstive \[email protected]\n\n\n \n020 7536 2028\n\n\n\n \nNotes for editors: \nAbout Sareum Holdings plc\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.\n \nSareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.\n \nSKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® ca...